Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD5363 and Paclitaxel in Advanced Gastric Adenocarcinoma
NCT02451956Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- Jan 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capivasertib in gastric adenocarcinoma, sponsored by Samsung Medical Center. Primary endpoint: Objective Response Rate at 24 weeks. Started Jan 2015; status: completed.
02
Drugs
capivasertib
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02451956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02451956.